American Society of Hematology

Figure 1.

$Figure 1. The time line and key events of the allogeneic/autologous CAR-T treatment regimen. The patient was diagnosed with ALL on day −1277 (−42.5 months) and received extensive chemotherapy but developed refractory relapses with lung infections. Maternal source CD19 CAR-T cells were prepared based on a 5- to 7-day CAR-T–cell preparation protocol as illustrated on the top. Allo–CAR-T cells were infused on days 0, 3, and 7, after conditioning chemotherapy. The patient achieved a partial response (PR) in 50 days and received an auto–CAR-T infusion on day 56 after conditioning chemotherapy. CR was achieved on day 77.$

The time line and key events of the allogeneic/autologous CAR-T treatment regimen. The patient was diagnosed with ALL on day −1277 (−42.5 months) and received extensive chemotherapy but developed refractory relapses with lung infections. Maternal source CD19 CAR-T cells were prepared based on a 5- to 7-day CAR-T–cell preparation protocol as illustrated on the top. Allo–CAR-T cells were infused on days 0, 3, and 7, after conditioning chemotherapy. The patient achieved a partial response (PR) in 50 days and received an auto–CAR-T infusion on day 56 after conditioning chemotherapy. CR was achieved on day 77.

This Feature Is Available To Subscribers Only